TheStreet downgraded Boston Scientific from a "B" to a "C" rating in a recent research report.
Here's what you should know.
1. TheStreet joins several other analysts in downgrading the industry giant.
2. Yet, despite the recent downgrades, Boston Scientific still has 13 "buy" ratings, six "hold" ratings and a single "sell" rating.
3. Analysts attached an average price target of $31.06 per share to the stock.